August 2, 2021 -- Ipsen and Exicure have signed an agreement giving Ipsen an exclusive option to license spherical nucleic acids Exicure is developing for Huntington's disease and Angelman syndrome.
Spherical nucleic acids are nanostructures that consist of densely packed, linear nucleic acids in a 3D spherical geometry. These structures have distinct chemical and biochemical properties compared to oligonucleotides that have been shown to enhance the cell penetration, biodistribution, and organ persistence properties of oligonucleotides.
Exicure will manage preclinical development of the acids, and if Ipsen exercises its option, it will be responsible for marketing. Ipsen will give Exicure a $20 million upfront payment. Exicure will also be eligible to receive up to $1 billion in milestone payments if Ipsen opts into both programs, as well as royalties, according to the two firms.
Copyright © 2021 scienceboard.net